Navigation Links
ETH Zurich researchers develop antibody test
Date:3/3/2008

ETH Zurich professor Peter Seeberger has been working on a sugar-based malaria vaccine for years. The new test takes him one important step closer to his goal. The malaria pathogen plasmodium falciparum carries poisonous sugar molecules called GPIs for short on its surface that are able to be individually identified. Professor See-bergers research team is now developing a new method that demonstrates that the malaria pathogens toxic sugar molecules trigger a specific immune reaction in adults.

Antibodies in blood from malaria regions

Tests show that blood samples taken from adults living in areas of Africa where malaria is endemic contain specific antibodies against particular GPIs. While infection is still possible despite the antibodies, the consequences are less serious. The immune system recognizes the poisonous sugar molecules as foreign bodies and blocks their toxic impact. Not living in high-risk areas, Europeans lack the relevant antibodies. As soon as Europeans are infected with malaria, the number of antibodies increases significantly. Subsequently, there is a direct link between the amount of antibodies and protection against the disease.

Inexpensive detection

This insight is thanks to a novel method for detecting antibodies. Faustin Kamena, a post-doc in Professor Seebergers lab, has developed a special chip that can, inexpensively and with minute quantities of blood serum and sugar molecules, determine whether or not someone has formed particular antibodies against various GPIs. To this end, the researchers use the purest possible GPIs. These can be produced synthetically and in large amounts in a laboratory, as the Seeberger team has demonstrated in earlier research.

The new method involves affixing over 64 pads comprising pinpoint dots to glass slides. Every little pad consists of several tiny heaps of different GPIs in varying concentrations. When blood serum is then administered to such a pad, possible antibodies specifically bind to certain sugar molecules. Dyes then reveal to which GPIs the antibodies have attached themselves.

Help for infants

Thanks to the information obtained from the chip, scientists can produce the specific sugar molecules that the immune system has to recognize. The findings on natural re-sistance subsequently acquired are crucial to developing a sugar-based malaria vaccine. This could prove particularly beneficial to children in malaria-infested regions.

The millions of malaria sufferers are primarily infants under the age of five as only adults develop antibodies against the malaria pathogens sugars. An infants immune system is incapable of recognizing and combating the toxic sugar molecules. Consequently, a new, selective vaccine is now called for. Professor Seeberger states: This evidence is another important step towards finding a malaria vaccine because we now know which antibodies protect adults.


'/>"/>

Contact: Peter Seeberger
seeberger@org.chem.ethz.ch
41-446-332-103
ETH Zurich/Swiss Federal Institute of Technology
Source:Eurekalert

Related biology news :

1. ETH Zurich competence center ESC introduces energy strategy
2. New ETH Zurich article published in scientific journal Nature
3. ETH Zurich professor Ari Helenius awarded Benoist Prize
4. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
5. Electronic structure of DNA revealed for 1st time by Hebrew University and collaborating researchers
6. Researchers offer new theory for dogfish and skate population outburst on Georges Bank
7. UCLA researchers solve decade-old mystery
8. Rats on islands disrupt ecosystems from land to sea, researchers find
9. Iowa State researchers help piece together the corn genomes first draft
10. U-M researchers release most detailed global study of genetic variation
11. LSU researchers challenge analyses on sustainability of Gulf fisheries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... Dec. 15, 2016   WaferGen Bio-systems, Inc. ... technology company, announced today that on December 13, 2016, ... of The Nasdaq Stock Market LLC which acknowledged that, ... of WaferGen,s common stock had been at $1.00 or ... regained compliance with Listing Rule 5550(a)(2) of the Nasdaq ...
(Date:12/12/2016)... -- Researchers at Trinity College, Dublin, are opening up ... material with Silly Putty. The mixture (known as "G-putty") ... sense pulse, blood pressure, respiration, and even the ... The research team,s findings were published Thursday in ... Due ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their ... Cancer ... reach $15,737 million by 2022 from $6,521 in 2015, growing at ... Omic technologies segment accounted for more than half of the revenue ...
(Date:1/19/2017)... and HOUSTON , Jan. ... Prenatal") today announced the formation of its Medical/Clinical ... clinicians and industry veterans who enhance the range ... it accelerates development of its novel prenatal diagnostic ... medical, clinical and strategic guidance for the company,s ...
(Date:1/19/2017)... , Jan 19, 2017 Research and Markets ... has announced the addition of the ... Application - Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future ... till 2025, using estimated market values as the base numbers ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... software to leading biopharmaceutical and medical device manufacturers and regulators, is proud to ... CFR Part 11-compliant email client designed to provide product vigilance departments with the ...
Breaking Biology Technology: